Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: A pilot study

Keyphrases

• Carboplatin 100%
• Hyperthermic Intraperitoneal Chemotherapy (HIPEC) 100%
• Platinum Sensitivity 100%
• Ovarian Carcinoma 100%
• Operative 37%
• Platinum-based 25%
• Secondary Cytoreductive Surgery 25%
• Tolerability 12%
• Ovarian Cancer 12%
• Cancer Recurrence 12%
• Platinum-resistant Ovarian Cancer 12%
• Quality of Life 12%
• Thrombocytopenia 12%
• Hyperthermic Intraperitoneal 12%
• Neutropenia 12%
• Overall Survival 12%
• Single Institution 12%
• Nausea 12%
• Disease-free Survival 12%
• Hospital Stay 12%
• Survival Data 12%
• Surgical Complications 12%
• Before Surgery 12%
• Treatment Delay 12%
• Expected Range 12%
• Forgoing 12%
• Completion of Therapy 12%
• Intraoperative Complications 12%
• Optimal Cytoreduction 12%
• Median Range 12%
• Prospective pilot Study 12%
• Suboptimal Cytoreduction 12%
• Intraperitoneal Carboplatin 12%
• OSCORE 12%
• Extra-abdominal 12%
• 6-23 Months 12%
• Chemotherapy Dose 12%
• 6-cycles 12%
• Abdominal Diseases 12%

Medicine and Dentistry

• Carboplatin 100%
• Krukenberg Tumor 100%
• Hyperthermic Intraperitoneal Chemotherapy 100%
• Quality of Life 12%
• Ovarian Cancer 12%
• Neutropenia 12%
• Postoperative Complication 12%
• Cancer Recurrence 12%
• Nausea 12%
• Overall Survival 12%
• Disease Free Survival 12%
• Thrombocytopenia 12%
• Therapy Delay 12%
• Peroperative Complication 12%
• Saralasin 12%
• Platinum-Sensitive Ovarian Cancer 12%
• Cytoreductive Surgery 12%
• Abdominal Disease 12%